Jay M. Edelberg

Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome

J Wouter Jukema, Deepak L. Bhatt, Deepak L Bhatt, 2018, The New England journal of medicine.

The inhibition of tissue type plasminogen activator by plasminogen activator inhibitor-1. The effects of fibrinogen, heparin, vitronectin, and lipoprotein(a).

S. Pizzo, J. Edelberg, C. Reilly, 1991, Journal of Biological Chemistry.

Ionic modulation of the effects of heparin on plasminogen activation by tissue plasminogen activator: the effects of ionic strength, divalent cations, and chloride.

S. Pizzo, J. Edelberg, S. Stack, 1992, Archives of biochemistry and biophysics.

Lipoprotein a inhibits streptokinase-mediated activation of human plasminogen.

S. Pizzo, M. Gonzalez-Gronow, J. Edelberg, 1989, Biochemistry.

Lipoprotein(a) inhibition of plasminogen activation by tissue-type plasminogen activator.

S. Pizzo, M. Gonzalez-Gronow, J. Edelberg, 1990, Thrombosis research.

Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome

Deepak L. Bhatt, R. Diaz, H. White, 2018, New England Journal of Medicine.

Alirocumab Reduces Total Nonfatal Cardiovascular and Fatal Events in the ODYSSEY OUTCOMES Trial†

K. Mahaffey, P. Tricoci, G. Steg, 2019, Journal of Clinical Lipidology.

Alirocumab in Patients With Polyvascular Disease and Recent Acute CoronarySyndrome

M. Szarek, A. Moryusef, R. Pordy, 2022 .